

SOUTH SUDAN

Support for DTP-HepB-Hib Vaccine

This Decision Letter sets out the Programme Terms of a Programme

1. Country:	South Sudan																									
2. Vaccine grant number:	14-SDS-08a-Y, 1416-SDS-04c-X, 17-SDS-04c-X, 18-SDS-04c-X, 1920-SDS-04c-X																									
3. Date of Decision Letter:	9/30/2019																									
4. Date of the Partnership Framework Agreement:	10 July 2013																									
5. Programme title:	New Vaccine Support (NVS), DTP-HepB-Hib, Routine																									
6. Vaccine type:	DTP-HepB-Hib																									
7. Requested product presentation and formulation of vaccine:	Penta, 10 doses per vial, LIQUID																									
8. Programme Duration:¹	2014-2020																									
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)																									
	2014-2019	2020	2021	2022	2023	2024	Total²																			
Programme Budget (US\$)	9,349,922	88,000	-	-	-	-	9,437,922																			
10. Vaccine introduction grant	<table border="1" style="width: 100%; border-collapse: collapse; margin-bottom: 10px;"> <thead> <tr> <th colspan="3" style="text-align: center;">Approval</th> </tr> <tr> <th style="text-align: center;">Year</th> <th style="text-align: center;">Grant Number</th> <th style="text-align: center;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">2014</td> <td style="text-align: center;">14-SDS-08a-Y</td> <td style="text-align: right;">301,240</td> </tr> </tbody> </table> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="2" style="text-align: center;">Disbursement</th> </tr> <tr> <th style="text-align: center;">Disbursement date</th> <th style="text-align: center;">Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">16 November, 2017</td> <td style="text-align: right;">(53,438)</td> </tr> <tr> <td style="text-align: center;">15 May, 2014</td> <td style="text-align: right;">184,758</td> </tr> <tr> <td style="text-align: center;">16 April, 2014</td> <td style="text-align: right;">169,920</td> </tr> </tbody> </table>							Approval			Year	Grant Number	Amount (US\$)	2014	14-SDS-08a-Y	301,240	Disbursement		Disbursement date	Amount (US\$)	16 November, 2017	(53,438)	15 May, 2014	184,758	16 April, 2014	169,920
Approval																										
Year	Grant Number	Amount (US\$)																								
2014	14-SDS-08a-Y	301,240																								
Disbursement																										
Disbursement date	Amount (US\$)																									
16 November, 2017	(53,438)																									
15 May, 2014	184,758																									
16 April, 2014	169,920																									
11. Product switch grant	Not applicable																									
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)																									

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

Type of supplies to be purchased with Gavi funds	2014-2019	2020	2021						
Number of vaccine doses		121,900	-						
Annual Amounts (US\$)	9,349,922	88,000	-						
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.								
14. Self-procurement:	Not applicable								
15. Co-financing obligations:	Not applicable								
16. Operational support for campaigns:	Not applicable								
17. Additional Reporting Requirements:	<table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received </td> <td>31 March 2020 15 May 2020</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>				Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received 	31 March 2020 15 May 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates								
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received 	31 March 2020 15 May 2020								
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat								
18. Financial clarifications:	Not applicable								
19. Other conditions:	Not applicable								

On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
30 September 2019